Abstract

You have accessJournal of UrologyCME1 Apr 2023MP39-14 THE RISK OF CATASTROPHIC HEALTHCARE EXPENDITURES AMONG PROSTATE AND BLADDER CANCER SURVIVORS IN THE UNITED STATES Benjamin V. Stone, Muhieddine Labban, Dejan K. Filipas, Edoardo Beatrici, Nicola Frego, Zhiyu (Jason) Qian, Sandeep S. Voleti, Stuart R. Lipsitz, Alexander P. Cole, and Quoc-Dien Trinh Benjamin V. StoneBenjamin V. Stone More articles by this author , Muhieddine LabbanMuhieddine Labban More articles by this author , Dejan K. FilipasDejan K. Filipas More articles by this author , Edoardo BeatriciEdoardo Beatrici More articles by this author , Nicola FregoNicola Frego More articles by this author , Zhiyu (Jason) QianZhiyu (Jason) Qian More articles by this author , Sandeep S. VoletiSandeep S. Voleti More articles by this author , Stuart R. LipsitzStuart R. Lipsitz More articles by this author , Alexander P. ColeAlexander P. Cole More articles by this author , and Quoc-Dien TrinhQuoc-Dien Trinh More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003277.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Little is known about the rates of catastrophic healthcare expenditures among survivors of prostate and bladder cancer or the factors that place patients at highest risk for undue cost. METHODS: The Medical Expenditure Panel Survey was utilized to identify prostate and bladder cancer survivors from 2011-2019. Rates of catastrophic healthcare expenditures (out-of-pocket healthcare spending >10% household income) were compared between survivors of all urologic cancer, prostate cancer, and bladder cancer versus adults without cancer. Significant differences were further explored with multivariable logistic regression to identify risk factors for catastrophic expenditures, including models with interaction terms for race, income, and insurance status. RESULTS: Among 2,620 urologic cancer survivors, corresponding to a weighted national estimate of 3,251,500 patients after application of survey weights, there were no significant differences in catastrophic expenditures among patients with prostate cancer compared to adults without cancer. Patients with bladder cancer had significantly greater rates of catastrophic expenditures (12.75% versus 8.33% with and without cancer, respectively, p=0.0273). Significant predictors of catastrophic expenditures in bladder cancer survivors included older age, comorbid illnesses, lower income, retirement, poor health status, and private insurance (Table 1). Among white patients, a bladder cancer diagnosis was not associated with increased odds of catastrophic expenditures (9.18% vs. 8.65%, OR 1.08, 95% CI 0.742 - 1.578), while in Black patients bladder cancer was associated with significantly increased odds of catastrophic expenditures (19.49% vs. 5.14%, OR 6.41, 95% CI 1.28 – 32.01, Figure 1). CONCLUSIONS: Bladder cancer survivorship is associated with a significant ongoing risk of catastrophic healthcare expenditures, particularly among Black patients. Interventions to mitigate disparities in the burden of cost should account for these differences in risk. Source of Funding: None. © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e540 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Benjamin V. Stone More articles by this author Muhieddine Labban More articles by this author Dejan K. Filipas More articles by this author Edoardo Beatrici More articles by this author Nicola Frego More articles by this author Zhiyu (Jason) Qian More articles by this author Sandeep S. Voleti More articles by this author Stuart R. Lipsitz More articles by this author Alexander P. Cole More articles by this author Quoc-Dien Trinh More articles by this author Expand All Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call